CAR-T: What Is Next?

The year 2017 was marked by the Food and Drug Administration (FDA) approval of the first two chimeric antigen receptor-T (CAR-T) therapies. The approved indications were for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and for the treatment of patients up to 25 years...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2023-01, Vol.15 (3), p.663
Hauptverfasser:	Chen, Yi-Ju, Abila, Bams, Mostafa Kamel, Yasser
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute lymphoblastic leukemia Acute lymphocytic leukemia Antigens B-cell lymphoma Cancer therapies Care and treatment Chemotherapy Chimeric antigen receptors Clinical trials Cytokines FDA approval Flow cytometry Hematology Lymphatic leukemia Lymphocytes Lymphocytes B Lymphomas Macrophages Malignancy Mutation Neurotoxicity Patients Remission (Medicine) Review Safety Side effects Signal transduction Solid tumors Steroids Transcription factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!